Viagra Vision Loss Concern Will Prompt Erectile Dysfunction Class Labeling, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's review of adverse event reports concludes there is no evidence of increased risk of non-arteritic anterior ischemic optic neuropathy – but the company is agreeing to include rare reports in labeling. Lilly reports a boost in Cialis' market share since late May, when the Viagra safety concerns came to light.